Skip to content
Home » Why Most Biotech Startups Fail Before Clinical Trials

Why Most Biotech Startups Fail Before Clinical Trials

Biotech founder reviewing IND readiness checklist with CMC and tox documents before clinical trials

Most biotech startups fail before clinical trials because you can’t clear the IND bar with promising science alone, you must deliver a complete, regulator-ready package across nonclinical safety, CMC, and a credible clinical plan before your runway expires. The failures look “quiet” from the outside, but they’re usually predictable inside the company months earlier.

This article shows where preclinical programs actually break, why investors stop funding them, and how you can spot the failure modes early enough to change course. You’ll get practical guidance on IND readiness, translation risk, CMC reality, and financing strategy that matches how biotech is evaluated in real diligence, not how pitch decks describe it.

Why Do Most Biotech Startups Fail Before They Ever Start Clinical Trials?

You fail pre-IND when the science risk and the company risk compound faster than your ability to remove uncertainty. In discovery, you can move quickly with small experiments and flexible narratives. The moment you commit to IND-enabling work, speed gets replaced by documentation, quality systems, and repeatability, and many teams are not built for that shift.

Capital amplifies the problem. Preclinical companies burn cash across parallel workstreams, pharmacology, toxicology, bioanalysis, formulation, process development, analytics, regulatory writing, and vendor oversight, long before human data exists. When fundraising tightens or milestones slip, you end up stuck with half-finished packages that are hard to finance because they don’t unlock a clean inflection point.

The industry math also drives harsh selection. If your program enters Phase I, the average likelihood of approval reported from Citeline’s 2014–2023 data is 6.7%, with Phase II at 28%, Phase I at 47%, Phase III at 55%, and 92% after filing for regulatory approval. That forces investors to demand stronger de-risking before first-in-human, which pushes more attrition earlier, and pushes marginal programs to die before they ever show up on a trial registry.

What Are The Top Specific Reasons A Biotech Can’t Reach An IND?

IND failure is rarely one dramatic event. It’s usually a pile-up of smaller misses that become non-negotiable when you try to assemble the submission. FDA describes the IND as the mechanism to obtain an exemption that allows interstate shipment and clinical investigation, and the early development goal centers on whether the product is reasonably safe for initial use in humans and shows activity that supports further development. If your package can’t support that, you stall.

In practice, the most common blockers cluster into a few categories. One is nonclinical gaps: your pharmacology story is incomplete, your exposure margins are unclear, or your tox plan doesn’t match the intended clinical route, schedule, or patient population. Another is CMC gaps: you can’t show control over identity, purity, potency, impurities, stability, comparability, or manufacturing consistency at a level that makes a first-in-human study defensible.

A third is regulatory mismatch. You submit what you think is “enough,” but your plan doesn’t align with what the review division expects for your modality and indication. That mismatch can trigger additional information requests, delayed starts, or a program reset that the company cannot afford. You avoid many of these surprises by using formal early interactions, including the FDA Pre-IND Consultation Program, which is explicitly intended to foster early communication on what data are needed to warrant IND submission and how to design nonclinical studies and initial development plans.

Is There Data On How Often Drug Programs Fail In Preclinical (Before Phase I)?

Preclinical attrition is high, and it’s also hard to measure cleanly because definitions differ across datasets. Many programs die before they are formally recorded as “candidates,” and many companies stop reporting failed assets once they pivot. That said, multiple sources and industry summaries point to steep attrition before Phase I, often because early leads do not survive the full stack of requirements needed for human dosing.

The more useful way to use “failure rate” data is to treat it as a warning about your burden of proof. Even after you clear the preclinical gates and start Phase I, the downstream probability of approval remains low on average, which is why investors force earlier de-risking and why marginal programs get cut before IND. The Citeline/Norstella phase transition numbers show the funnel stays unforgiving across clinical stages, and Phase II remains the most common attrition point, which makes early translation evidence a central diligence focus.

You also need to separate “science failure” from “package failure.” A molecule can work biologically yet still fail the IND path because you can’t manufacture it consistently, can’t validate the assay you used to make decisions, or can’t justify the human starting dose. Those are preventable failures if you treat preclinical like product development under regulation, not academic exploration.

How Much Money And Time Does It Take To Get To A First-In-Human Trial, And Why Do Startups Run Out Of Runway First?

Time-to-IND varies widely by modality and starting point, but the structure of the work is consistent: discovery and lead selection, then IND-enabling pharmacology, toxicology, and CMC, then the clinical protocol and operational readiness. The trap is that early teams budget as if each stream is linear. Your reality is concurrency: tox influences formulation, formulation influences bioanalytical methods, methods influence comparability, comparability influences manufacturing, manufacturing influences stability, and stability influences clinical supply timing.

Runway failure usually stems from planning errors you can identify early. You set milestones that sound like progress, “finish lead optimization,” “complete scale-up,” “start GLP,” without tying them to a financing event that investors recognize as value creation. You also underestimate vendor management load. CROs and CDMOs do not replace internal ownership, they replace hands-on bench work, and if you do not manage them tightly you pay twice: once in invoices and again in time.

Regulatory timing adds friction that founders often dismiss until it’s too late. An IND is not only data, it’s a coordinated submission that must be internally consistent, traceable, and aligned with what you plan to do in humans. FDA’s IND overview makes clear the sponsor’s goal in early preclinical development is establishing reasonable safety for initial human use and collecting the data needed to avoid unreasonable risks in limited early-stage studies. That demands planning backward from the clinical protocol, not forward from a mouse result.

Why Do Preclinical Results So Often Fail To Translate To Humans?

Translation fails when you build certainty on models that were never designed to predict human outcomes. Many animal models reproduce a phenotype, not a human disease mechanism. Many in vitro assays measure a convenient proxy, not a clinically meaningful pathway. When you carry those signals into expensive IND-enabling work without human relevance checks, you build a company on a fragile foundation.

Clinical failure analyses point to the dominant reasons: lack of efficacy and toxicity. A peer-reviewed review in PMC summarizing 2010–2017 clinical failures attributes a large share to lack of clinical efficacy (40%–50%) and unmanageable toxicity (30%), with additional contributions from poor drug-like properties and strategic or commercial issues. Those percentages matter pre-IND because they tell you where diligence will focus: human relevance, exposure-response, safety margins, and patient selection logic.

Translation risk is also a design problem. If you do not define what “success” means in humans, you cannot design preclinical experiments that meaningfully support that goal. You end up accumulating positive signals that don’t connect to a dosing strategy, a biomarker plan, or a patient population. When you later attempt to craft an IND and a Phase I protocol, the gaps become visible, and financing breaks at the worst possible moment.

What Do Founders And Employees Say Are The Biggest Preclinical Failure Modes?

Operator conversations are blunt: the most common themes are runway stress, unclear feasibility, and leadership promising timelines that don’t match the work required. Reddit threads in r/biotech repeatedly show people asking whether to shut down, how to evaluate a small startup role, and how to interpret layoffs at preclinical companies, which signals how often the “quiet” preclinical phase becomes a sudden business crisis. When employees start questioning the realism of the plan, it usually means internal milestones are slipping or fundraising is failing.

The operational failure modes repeat. You over-index on hiring “platform” talent without a program plan that can reach IND, so your burn rises while IND-critical deliverables stay vague. You confuse activity with progress, running more screens, more omics, more model work, while CMC, tox strategy, and regulatory writing stay under-resourced. When the board asks for an IND timeline you respond with optimism instead of a work-breakdown structure.

Morale issues then become execution issues. If your team senses the company cannot finance the next six to twelve months, they stop taking smart risks and start optimizing for personal safety. Vendor work slows because approvals slow. Quality discipline slips. At that point, even strong science can’t save the company because the machine that turns science into an IND package is no longer functioning.

What Can You Do Differently To Improve Your Odds Before Clinical Trials?

Start by treating IND readiness as an engineering program with traceable requirements. Your target product profile, intended clinical population, route of administration, and dosing schedule must drive every nonclinical and CMC decision. If those inputs are not locked, you will redo expensive studies when the clinical plan changes. That rework is one of the fastest ways to die pre-IND.

Use early FDA interactions to force specificity. The FDA Pre-IND Consultation Program is designed to facilitate early communication and provide advice on data needed to support testing in humans, nonclinical study design, and IND requirements, and it emphasizes contacting the agency early so recommendations can shape your plan. Even if your division is not within that specific program scope, the operating principle holds: ask targeted questions early, document the answers, and align vendors and timelines around them.

Then align financing with real inflection points. Investors fund uncertainty reduction, not effort. You need milestones that change the risk profile in a way that can be defended in diligence: a GLP tox outcome with interpretable margins, a validated bioanalytical method that supports exposure claims, a reproducible CMC process with defined controls, a translatable biomarker plan tied to clinical endpoints. If you can’t articulate how each dollar buys down a specific risk, you won’t raise when the market tightens.

Why Do Biotech Startups Fail Before Clinical Trials?

  • Run out of runway before IND-enabling tox, CMC, and regulatory work finish
  • Preclinical efficacy doesn’t translate, or safety margins collapse
  • Manufacturing and quality controls aren’t IND-ready

Build An IND-Ready Company, Not Just A Promising Program

You don’t reach clinical trials by collecting more encouraging data, you reach them by assembling a complete, consistent IND package that withstands scrutiny under time pressure. Your highest leverage move is shifting your operating system early: plan backward from the first-in-human protocol, fund the work that removes the biggest risks, and force operational discipline in CMC, tox, bioanalysis, and documentation. Use early regulatory communication to align expectations, and treat vendor oversight as a core internal competency rather than an administrative task. If you implement those habits, you stop being surprised by pre-IND failure modes and start deciding, early, which risks are worth paying for.

References

Tags: